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Purpose: Recent studies have illuminated the vitreous proteome as a potentially important diagnostic tool that will predict
disease progression and response to treatment, in eyes with retinal disease. Studies to date have demonstrated correlations
of protein levels between vitreous and aqueous humor. Because these results are un-expected and analysis was only done
on a few endpoints, the present study further analyzes the relationship between aqueous and vitreous by probing a wide
array of proteins in patients with posterior segment diseases.
Methods: Anterior chamber aqueous fluid was obtained using a limbal approach with a 30 gauge needle. Immediately
following, the vitreous sample was obtained via a pars plana approach. A 25 gauge needle with a 1 ml syringe was directed
into the mid-vitreous cavity and vitreous fluid was gently aspirated. Aqueous and vitreous samples were then analyzed
using the quantitative native protein analysis method called reverse phase protein microarray technology (RPPM).
Results: The entire sample population (n=11) was probed against 34 proteins, revealing 8 proteins that significantly
correlate, 3 proteins that trend to correlation but fell short of significance and 23 proteins that have no correlation between
the vitreous and aqueous humor.
Conclusions: Proteins in the aqueous cannot be assumed to correlate with their counterparts in the vitreous.
Recent reports have begun focusing on the presence and
level of various proteins in intraocular fluid as markers of
retinal disease [1-8]. This raises the opportunity to apply new
technologies to study proteins found in intraocular fluid as
markers for the identification, and prediction of treatment
response in retinal disorders. One recent study demonstrated
the  ability  to  identify  activated  cell  receptors  and  other
proteins in vitreous aspirates, and found certain activated cell
receptor proteins that correlate with response to bevacizumab
treatment,  suggesting  that  response  to  certain  treatment
options may be predicted by proteins in the vitreous [1].
The current school of thought is that aqueous samples are
much easier to obtain from patients than a vitreous aspirate,
because  of  past  studies  showing  that  the  success  rate  of
vitreous aspiration only around 35% [9]. However, our studies
have shown that with proper technique, a 95% success rate
can  be  achieved  when  performing  in-office  vitreous
aspirations [10]. This led us to study the difference in vitreous
and  aqueous  composition,  to  attempt  to  understand  the
differences and similarities of protein composition between
the two chambers.
Although it is expected that the vitreous and aqueous
would have different protein composition, previous studies on
a small number of proteins have shown that the vitreous and
aqueous protein levels do correlate [2,4,11]. Therefore, it is
natural to ask about the relationship of protein levels in the
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vitreous  and  aqueous  when  considering  optimal  sampling
strategies. This is especially important considering that there
are different cell types populating the two chambers that are
likely to contribute different proteins in addition to shared
proteins.
The  current  study  employs  a  reverse  phase  protein
microarray (RPPM) based assay, which allows quantitative,
high throughput, highly sensitive, simultaneous analysis of
multiple proteins in their native state, using small sample
volumes (50–100 μl) of either aqueous or vitreous [1,10,12,
13], to discover the similarities and differences of the vitreous
and aqueous humor proteomes.
METHODS
Subjects: All enrolled patients completed informed consent
for the surgical procedure and study, which was performed
with full IRB approval (Western institutional review board,
Olympia, WA) and adhered to the tenets of the Declaration of
Helsinki.  Every  patient  in  the  study  had  a  vitreo-retinal
condition (see Table 1) that required surgical intervention
which  was  performed  by  the  same  surgeon  (B.M.G.).
Exclusion criteria included patients with any of the following:
(1)  History  of  cataract  surgery,  (2)  active  or  previous
intraocular  inflammation,  (3)  anterior  segment
neovascularization or disease (conjunctival, corneal, iris, lens
capsule) except for cataract, (4) retinal or ciliary body dialysis,
or (6) unable to understand or complete informed consent.
Sampling  technique:  A  standard  aqueous  and  vitreous
sampling protocol was followed for all patients as follows:
Following retrobulbar anesthesia, the patient was prepped and
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2856draped in a sterile fashion in the operating room. After a sterile
lid speculum was placed, an infusion cannula was placed in
the infratemporal quadrant for safety purposes. Once inserted,
the infusion cannula remained in the off position until all
sampling was completed. Anterior chamber aqueous fluid was
obtained (0.05 ml) using a limbal approach with a 30 gauge
needle (PrecisionGlide®; Becton Dickinson, Franklin Lakes
NJ). Immediately following successful aqueous fluid sample,
the vitreous sample was obtained via a pars plana approach.
A 25 gauge needle (Terumo Needle; Terumo Corporation,
Elkton, MD) with a 1 ml syringe (PrecisionGlide®; Becton
Dickinson) was directed into the mid-vitreous cavity and 0.05
to  0.10  ml  of  vitreous  fluid  was  gently  aspirated.  After
removal,  the  syringe  was  capped,  transferred  to  ice,  and
immediately  transferred  to  a  negative  80  °C  freezer  for
storage. Once the aqueous/vitreous sampling was completed,
the infusion line was inspected for proper placement and the
remainder of the case was completed. No intravitreal drugs
were administered during the course of this study to any of the
patients.
Proteomic analysis: A total of 34 proteins (Table 2) which
represent  endpoints  from  signaling  pathways,  such  as
angiogenesis, apoptosis, hypoxia/ischemia, oxidative stress,
inflammation, and remodeling, all of which are known to be
a part of vitreoretinal diseases [14-17] were selected to be
studied.  The  selected  proteins  vary  in  size,  confirmation,
cellular  localization,  charge,  and  hydrophobicity.  This
amount of variation is used to ensure that there is no physical
property  or  signaling  pathway  that  specifically  associates
between the vitreous and aqueous, while others do not. The
results reported here use this method to greatly expand the
number of proteins that have been studied, which adds to the
current knowledge base of biochemical reactions within the
eye.
Vitreous and aqueous samples were analyzed by reverse
phase  protein  microarray  technology  following  the  same
protocol as described in [1]. Briefly, the samples were diluted
in  extraction  buffer  (T-PER  [Pierce,  Indianapolis,  IN],  2-
mercaptoethanol  [Sigma,  St  Louis,  MO],  and  2×  sodium
dodecyl  sulfate  Tris-glycine  loading  buffer  [Invitrogen,
Carlsbad, CA]) prior to being plated in microtiter plate. The
lysates  were  printed  on  glass-backed  nitrocellulose  array
slides (FAST Slides; Whatman, Florham Park, NJ) using an
Aushon 2470 arrayer (Aushon BioSystems, Burlington, MA)
equipped with 350-μm pins. Each lysate was printed in a
dilution curve representing undiluted and 1:2, 1:4, 1:8, and
1:16 dilutions. The slides were stored with desiccant (Drierite;
WA  Hammond,  Xenia,  OH)  at  –20  °C  prior  to
immunostaining.  Immunostaining  was  performed  on  an
automated  slide  stainer,  following  the  manufacturer’s
instructions (Autostainer CSA kit; Dako, Fort Collins, CO)
using  polyclonal  primary  antibodies  and  biotinylated
secondary antibodies.  Thirty four (34) primary antibodies
were each incubated on their own slide at room temperature
for 30 min, while two negative control slides incubated in the
same manner with antibody diluents only on their own slides.
All antibodies (Table 2) were previously validated in-house
via western blot, and quality control RPPMs were printed with
cellular controls and stained at multiple dilutions to determine
the best signal/noise ratio. Each sample was printed onto 40
slides in duplicate along with standard cellular controls for the
purpose  of  inter-slide  precision,  and  data  normalization.
These controls include: A431+ EGF (BD Transduction Labs,
San Jose, CA), A431 Cell lysate (BD Transduction Labs),
BSA  (ThermoScientific,  Rockford,  IL),  and  HeLa
Pervanadate cells (BD Transduction Labs). Microarray spot
analysis was completed in the same manner as described in
[1,13].  Briefly, each array was scanned and spot intensity
calculated  using  ImageQuant  v5.2  (GE  Healthcare,
Piscataway, NJ), each spot duplicate was averaged and the
data  was  normalized  in  Microsoft  Excel  (Microsoft,
Redmond, WA) by subtracting the background noise from the
negative slide and compared to one of the control cell lysates
resulting in a single data point for each sample that could be
compared to every other sample on the array.
Statistical analysis: All statistical analysis was done using
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The
TABLE 1. PATIENT POPULATION DEMOGRAPHICS.
Patient number Age Diagnosis Vitrectomy before surgery? Eye
Patient 1 65 Macular hole/Macular Pucker No OD
Patient 1* 65 Recurrent Macular Hole Yes OD
Patient 2 88 Retinal Detachment/Vitreous Membranes Yes OD
Patient 3 34 Retinal Detachment/Vitreous Membranes No OS
Patient 4 68 Macular hole/Macular Pucker No OS
Patient 5 71 Retinal Detachment No OD
Patient 6 67 Macular Hole No OD
Patient 7 72 Macular Hole No OS
Patient 8 50 Retinal Detachment No OS
Patient 9 69 Macular Hole Yes OS
Patient 10 90 Retinal Detachment No OS
         Patient 1 had an initial sample taken before undergoing vitrectomy during macular hole surgery, Patient 1* represents the sample
         that was taken from this patient after a subsequent surgery to repair the recurrent macular hole.
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2857protein  data  was  reported  as  relative  intensity  units  as
described in [12,13], a unit that expresses the quantitative
abundance of the protein compared to background, and a
paired  t-test  was  used  to  compare  the  protein  levels.  To
examine the correlations between the aqueous and vitreous,
Shapiro-Wilk normality testing was performed for each group
to determine the distribution of the data. Since the data are not
normally  distributed,  the  Spearman’s  Rho  correlation
coefficient [18] was calculated for each protein. Probability
values for the Spearman’s correlations were then calculated
based on the t-distribution. A two-tailed p-value of less than
0.05 indicated statistical significance for both analyses. Ratio
data  was  generated  using  the  Bland-Altman  comparison
method  comparing  vitreous  sample  to  matching  aqueous
sample; the resulting data are graphically represented. Further
pathway  analysis  was  performed  using  Pathway  Studio
(Ariadne Genomics, Rockville, MD) to understand how the
proteins are interacting. All statistical work was reviewed and
approved by the faculty at The Johns Hopkins Biostatistics
Center (Baltimore, MD).
RESULTS
The study population included 10 patients with a total of 11
samples, which were all obtained in a surgical setting, with no
intravitreal drug administered. One patient required a repeat
operation for a chronic macular hole, and a second sample was
obtained at this time (Patient 1*). Furthermore, two others
(Patient 2 and 9) had vitrectomized eyes at the time of sample
collection. The average time between prior vitrectomy and
sampling for this study is 13 weeks, ranging from 3 weeks to
25 weeks. The patient population consisted of three male
patients and seven female patients, while all involved eyes
were phakic. The average age was 68.27 (range 34–90; See
Table 1).
TABLE 2. LIST OF ANTIBODIES AND MANUFACTURES USED IN THIS STUDY.
Antibody Primary pathway Company City, state
αβ crystallin Ocular Structure Assay Designs Plymouth Meeting, PA
AKT T308 Apoptosis/Survival Cell Signaling Danvers, MA
BAD S112 Apoptosis/Survival Cell Signaling Danvers, MA
BCL2 T56 Apoptosis/Survival Cell Signaling Danvers, MA
Musashi Cell Death/Apop. Cell Signaling Danvers, MA
AMPK α1 S485 Hypoxia/Ischemia Assay Designs Plymouth Meeting, PA
cABL T735 Oxidative Stress Cell Signaling Danvers, MA
HemeOxygenase 1 Oxidative Stress Assay Designs Plymouth Meeting, PA
Integrin α5β1 Adhesion/Migration Millipore Billerica, MA
COX-2 Oxidative Stress Invitrogen Carlsbad, CA
C3a Inflammation Abcam Cambridge, MA
C5a Inflammation Abcam Cambridge, MA
C9 Inflammation Abcam Cambridge, MA
CF-H Inflammation Aby Shop Gentofte, Denmark
IL-10 Inflammation Abcam Cambridge, MA
IL-12 Inflammation Abcam Cambridge, MA
IL-1β Inflammation Cell Signaling Danvers, MA
IL-8 Inflammation Abcam Cambridge, MA
IL-6 Inflammation Abcam Cambridge, MA
TNF-α Inflammation/Angio. Cell Signaling Danvers, MA
cKIT Y703 Angiogenesis Invitrogen Carlsbad, CA
cKIT Y719 Angiogenesis Cell Signaling Danvers, MA
FGFR Y653/654 Angiogenesis Cell Signaling Danvers, MA
PDGFRβ Y716 Angiogenesis Millipore Billerica, MA
PDGFRβ Y751 Angiogenesis Cell Signaling Danvers, MA
VEGF-A Angiogenesis Santa Cruz Santa Cruz, CA
VEGFR2 Y1175 Angiogenesis Cell Signaling Danvers, MA
VEGFR2 Y951 Angiogenesis Cell Signaling Danvers, MA
VEGFR2 Y996 Angiogenesis Cell Signaling Danvers, MA
PEDF Angiogenesis Millipore Billerica, MA
MMP-14 Remodeling/Angio. Abcam Cambridge, MA
MMP-2 Remodeling/Angio. Cell Signaling Danvers, MA
MMP-9 Remodeling/Angio. Cell Signaling Danvers, MA
TIMP2 Remodeling/Angio. Abcam Cambridge, MA
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quantified  and  a  paired  t-test  and  Spearman’s  correlation
coefficient  were  calculated.  Aqueous  and  vitreous  protein
values were analyzed for the total study population (n=11).
Vitreous  and  aqueous  correlation  analysis  with  all
patients: The entire sample population was investigated via
RPPM for 34 proteins. This process revealed eight proteins
that significantly correlated between the vitreous and aqueous
humor:  AKT  Threonine  308,  (AKT  T308;  ρ=0.6727,
p=0.0233), BCL-2 Associated Death Promoter Serine 112,
(BAD  S112;  ρ=0.6727,  p=0.0233),  B  cell  lymphoma  2
Threonine  56,  (BCL2  T56;  ρ=0.6727,  p=0.0233),
Complement  component  5a,  (C5a;  ρ=0.9091,  p=0.0001),
Complement  component  9,  (C9;  ρ=0.6818,  p=0.0208),
Complement  Factor  H,  (CF-H;  ρ=0.9273,  p=<0.0001),
Fibroblast Growth Factor Receptor Tyrosine 653/654 (FGFR
Y653/654;  ρ=0.6545,  p=0.0289),  and  Musashi  (ρ=0.8273,
p=0.0017).
Another subset of proteins trends toward correlation, but
falls just short of being statistically significant. This subset
includes: Cyclooxygenase 2 (COX-2; ρ=0.5909 p=0.0556),
Interleukin-6  (IL-6;  ρ=0.5989  p=0.0516),  and  Vascular
Endothelial Growth Factor A (VEGFA; ρ=0.6000 p=0.0510).
The remaining 23 screened proteins did not correlate in any
significant way between the aqueous and the vitreous.
To visualize this data, ratios of the vitreous versus the
aqueous  levels  for  each  protein  and  in  each  patient
combination were calculated and graphed. A true correlation
between  the  vitreous  and  aqueous  would  demonstrate  a
constant  ratio  of  level  of  expression  between  both
compartments, and would be expected for all patients as can
be seen in Figure 1 using CF-C5 and CF-H, which show a
strong correlation in their levels between the vitreous and
aqueous. In contrast, and representative of the majority of
proteins studied, Figure 2 shows an example of TNF-α and
PEDF where neither protein shows a significant correlation
between the aqueous and vitreous. The variation in ratios from
patient  to  patient  exemplifies  the  protein  level  difference
between the two chambers.
Protein network studies were done using Pathway Studio
(Ariadne Genomics, Rockville, MD) to understand why the
proteins that correlate between the aqueous and vitreous are
correlating, and why the others are not. The proteins found to
correlate between the aqueous and vitreous are a mainly part
of  two  biologic  groups,  apoptosis,  specifically  negative
regulation of apoptosis (GOgroup: 0043066) and alternative
complement pathway activation (GOgroup: 0006957) and on
a physical level, the 8 proteins that correlate are variable in
size, charge and hydrophobicity. The proteins that do not
correlate are not a part of either of these biologic processes,
Figure 1. Demonstrates how the ratio of
vitreous  to  aqueous  protein  levels  is
relatively  constant  for  2  proteins  that
showed a good correlation between the
aqueous and vitreous. Patient 1 has no
ratio level for CF-H because there was
no detectable expression of this protein
in the aqueous sample.
Figure 2. Graphical representation of the
ratio of vitreous to aqueous levels of
PEDF and TNF-α. These graphs display
the marked difference in correlation of
vitreous  and  aqueous  protein  levels
from patient to patient.
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2859TABLE 3. PATHWAY PROTEIN INTERACTIONS THAT ARE EXCLUSIVE TO THE AQUEOUS OR THE VITREOUS.
Vitreous Aqueous
Antibody Antibody Rho p-value Antibody Antibody Rho p-value
AKT T308 PDGFR Y716 0.855 2.20E-04 αB-Crystallin AKT T308 0.875 4.00E-04
AKT T308 TIMP2 0.914 8.40E-05 αB-Crystallin BAD Ser112 0.799 3.00E-03
AMPK a1 S485 BCL2 T56 0.888 0.001 αB-Crystallin cKIT Y703 0.909 1.00E-04
AMPK a1 S485 COX2 0.802 0.003 αB-Crystallin CF-H 0.763 6.00E-03
AMPK a1 S485 HemeOx-1 0.937 1.80E-05 αB-Crystallin FGFR 0.911 1.00E-04
AMPK a1 S485 IL-8 0.943 1.40E-05 αB-Crystallin MMP-2 0.89 2.00E-04
AMPK a1 S485 IL-10 0.878 3.70E-04 αB-Crystallin PDGFR Y751 0.785 4.00E-03
AMPK a1 S485 MMP-9 0.82 2.00E-03 αB-Crystallin VEGFR2 Y951 0.864 6.00E-04
AMPK a1 S485 Musashi 0.93 3.40E-05 BAD Ser112 FGFR 0.919 6.50E-05
BAD Ser112 COX2 0.873 5.00E-04 BCL2 T56 FGFR 0.919 6.50E-05
BAD Ser112 PDGFR Y716 0.808 8.00E-03 BCL2 T56 IL-12 0.782 4.00E-03
BAD Ser112 PDGFR Y751 0.75 3.00E-03 BCL2 T56 MMP-14 0.858 1.00E-03
BAD Ser112 TIMP2 0.794 4.00E-03 BCL2 T56 VEGFR2 Y951 0.87 4.90E-04
BAD Ser112 VEGFR2 Y996 0.857 1.00E-03 cABL T735 CF-H 0.801 3.00E-03
BCL2 T56 COX2 0.861 1.00E-03 cKIT Y719 Integrin a5b1 0.862 2.00E-03
BCL2 T56 IL-1B 0.821 2.00E-03 cKIT Y719 PDGFR Y716 0.764 6.00E-03
BCL2 T56 IL-8 0.782 4.00E-03 cKIT Y719 PDGFR Y751 0.823 2.00E-03
BCL2 T56 Musashi 0.759 7.00E-03 C3a Integrin a5b1 0.8 3.00E-03
BCL2 T56 PDGFR Y716 0.782 4.00E-03 C5a TNF alpha 0.801 3.00E-03
BCL2 T56 PDGFR Y751 0.786 6.00E-03 C5a VEGFA 0.891 2.40E-04
BCL2 T56 VEGFR2 Y951 0.906 1.20E-04 C9 MMP-2 0.861 1.00E-03
BCL2 T56 VEGFR2 Y996 0.904 1.40E-04 C9 PDGFR Y716 0.793 4.00E-03
cABL T735 HemeOx-1 0.874 4.40E-04 C9 PDGFR Y751 0.784 4.00E-03
cABL T735 IL-1B 0.866 1.00E-03 C9 TIMP2 0.81 3.00E-03
cABL T735 IL-10 0.87 1.00E-03 FGFR MMP-9 0.835 1.40E-03
cABL T735 PDGFR Y716 0.804 3.00E-03 FGFR VEGFR2 Y951 0.814 2.30E-03
cABL T735 PEDF 0.782 4.00E-03 FGFR VEGFR2 Y996 0.81 2.50E-03
cKIT Y703 COX2 0.862 1.00E-03 IL-1B VEGFR2 Y951 0.762 6.00E-03
cKIT Y703 IL-1B 0.815 2.00E-03 Integrin a5b1 TNF alpha 0.801 3.00E-03
cKIT Y703 IL-10 0.762 6.00E-03 MMP-2 MMP-14 0.853 9.00E-04
cKIT Y703 MMP-14 0.86 1.00E-03 MMP-2 VEGFR2 Y951 0.82 2.00E-03
cKIT Y703 TIMP2 0.886 2.90E-04 MMP-9 MMP-14 0.862 1.00E-03
cKIT Y719 MMP-2 0.788 4.00E-03 MMP-14 VEGFR2 Y996 0.77 5.60E-03
COX2 MMP-9 0.888 2.60E-04 TNF alpha VEGFA 0.893 1.00E-03
COX2 TIMP2 0.809 3.00E-03        
COX2 VEGFR2 Y951 0.823 2.00E-03        
HemeOx-1 IL-1B 0.875 4.20E-04        
HemeOx-1 IL-8 0.915 7.90E-05        
HemeOx-1 Musashi 0.896 1.90E-04        
HemeOx-1 TNF alpha 0.786 4.00E-03        
HemeOx-1 VEGFR2 Y996 0.847 1.00E-03        
HemeOx-1 VEGFR2 Y1175 0.823 2.00E-03        
IL-1B IL-8 0.854 1.00E-03        
IL-1B IL-10 0.932 2.90E-05        
IL-1B Musashi 0.801 1.90E-04        
IL-8 IL-10 0.794 4.00E-03        
IL-8 Musashi 0.989 7.60E-09        
IL-8 VEGFR2 Y996 0.822 2.00E-03        
IL-10 Integrin a5b1 0.777 5.00E-03        
IL-10 MMP-2 0.889 1.00E-04        
IL-10 PDGFR Y716 0.932 2.90E-05        
IL-10 PDGFR Y751 0.839 1.00E-03        
IL-10 TNF alpha 0.819 2.00E-03        
IL-10 VEGFR2 Y996 0.911 9.60E-05        
Integrin a5b1 MMP-2 0.796 3.00E-03        
MMP-9 PDGFR Y751 0.788 4.00E-03        
MMP-14 TIMP2 0.89 2.40E-04        
MMP-14 VEGFR2 Y951 0.89 2.40E-04        
Musashi VEGFR2 Y996 0.784 4.00E-03        
Musashi VEGFR2 Y1175 0.773 5.00E-03        
PDGFR Y716 TIMP2 0.845 1.00E-03        
PDGFR Y716 TNF alpha 0.817 3.00E-03        
PDGFR Y751 TIMP2 0.896 1.90E-04        
PDGFR Y751 TNF alpha 0.809 3.00E-03        
PEDF VEGFR2 Y1175 0.899 1.60E-04        
TIMP2 VEGFR2 Y951 0.802 3.00E-03         
TIMP2 VEGFR2 Y996 0.792 4.00E-03        
TNF alpha VEGFR2 Y996 0.823 2.00E-03        
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2860but are variable in their physical attributes. There is also a
possibility that because of the different cellular composition
around each of the chambers that the proteins produced are
different, which leads to different interactions and binding
partners for the proteins that are screened in this study. Still,
we cannot definitively say that proteins that are a part of these
pathways/processes would always track between the aqueous
and vitreous.
To get a better understanding of the differences in protein
interactions  that  occur  in  the  aqueous  and  the  vitreous,
Spearman’s Rho analyses were performed (See Table 3). This
data continues to show that the aqueous and vitreous have
different proteomes.
All of the samples that were taken post vitrectomy were
compared to the group of samples that had no prior vitrectomy
(Table 1). The post vitrectomy group was too small to make
any  significant  conclusions,  but  investigating  the  pre-
vitrectomy samples alone did demonstrate that the majority of
the proteins screened still did not correlate between vitreous
and aqueous samples.
Additionally, Patient 1 had the first samples taken before
any  vitrectomy  procedure  had  been  performed,  while  the
second sample set was taken 6 months after the patient had a
vitrectomy. The ratios of vitreous to aqueous protein levels
were graphed to visualize the difference in the correlation of
the levels post vitrectomy (Figure 3). The ratios of the analyte
levels between the vitreous and aqueous demonstrate more
correlation between aqueous and vitreous after vitrectomy, yet
there is still variation in the ratio from protein to protein. This
data is very compelling, but must be studied in a broader group
to see if this trend continues.
DISCUSSION
Mounting  evidence  from  several  studies  to  date  have
demonstrated  that  proteins  in  the  vitreous  correlate  with
occurrence and stage of various retinal disorders [1,3,5,7,
19-21].  Such  biomarkers  could  lead  to  improved
understanding of retinal disease and enable the true realization
of individualized treatment for a wide range of blinding retinal
disorders.
The  vitreous  and  the  aqueous  are  contained  in  two
separate compartments that do not flow into one another.
Although there may be some exchange of proteins between
the  chambers  one  cannot  automatically  conclude  that  all
proteins present in the aqueous are derived from the retina,
since the aqueous chamber is lined with its own unique cell
types such as corneal endothelial cells, trabecular mesh work
cells, lens cells, and iris cells (Figure 4). The vitreous chamber
also has unique cell types including the cells of the retina, optic
Figure 4. A cross-cut illustration demonstrating how proteins are
likely to be produced in the aqueous and vitreous.
Figure 3. Represents the difference in
the protein level ratios between aqueous
and vitreous samples that were taken pre
and  post  vitrectomy  (Patient  1  and
Patient 1*, respectively).
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2861nerve, choroid, retinal pigment epithelium (RPE cells) and at
times, newly formed vitreous blood vessels (Figure 4). When
analyzing  similarities  and  differences  between  the  two
compartments, various factors such as lens status, vitreous
structure, disease state, and protein size must be considered.
Differing rates of protein synthesis and metabolism between
the aqueous and vitreous could produce differences in the
proteome  of  each  respective  segment.  The  differences  in
tissue  type  between  the  two  compartments  may  also
contribute to a quantitative difference in levels of various
proteins.
In disease states localized to the retina and choroid such
as macular degeneration, protein levels in the vitreous may be
a better indicator than protein levels in the aqueous. Studying
the pathobiology of vitreoretinal diseases would seemingly be
most effective by probing the vitreous because of its close
proximity to the retina, and thus a better sample to interrogate
for biomarkers of retinal diseases or clues toward new retinal
disease treatments.
Of  the  thirty-four  (34)  proteins  analyzed,  statistically
significant correlations between aqueous and vitreous levels
occurred  in  only  eight  (8)  proteins  and  strong  (yet  not
statistically significant) trends could be seen in only three (3)
additional  proteins.  The  8  correlating  proteins  are
representative of the apoptosis and complement activation
protein families, but there is no known reason to assume why
these particular proteins would correlate, whereas the other
24 do not.
Past  reports  have  analyzed  VEGF  levels  in  both
compartments and hypothesized that anterior segment levels
reflect the levels in the vitreous [6]. This hypothesis has been
supported by a publication reporting corresponding aqueous
and vitreous levels of VEGF and IL-6 in diabetic retinopathy
patients [4]. Even though this study was done on a small set
of  heterogeneous  patients,  we  do  achieve  statistically
significant data, and with our ability to do this in 34 proteins,
the work presented expands on the past studies regarding the
correlation of levels of VEGF-A and IL-6 between aqueous
and vitreous samples in the same patient [4,11]. Expanding
the number of investigated proteins shows that not all proteins
track each other between the aqueous and vitreous. These
results  show  a  positively  trending  correlation  (short  of
statistically significant) for the same two (2) proteins (VEGF-
A  and  IL-6),  however,  this  study  found  absolutely  no
correlation in 24 of 34 total proteins. To the best of this group’s
knowledge, no one has reported extensive correlating protein
levels measured in the vitreous and the aqueous of humans or
in animal studies. Further studies on the correlation of protein
markers between the aqueous and vitreous in other diseases
and in “normal” samples would be ideal to learn how the
interaction of proteins between the bodies changes depending
on diseases state, unfortunately this type of study could not be
performed due to the unnecessary invasive procedures that
would be done on healthy individuals, but animal studies
could be developed to understand the correlation further.
The  work  presented  here  does  support  the  previous
studies comparing the aqueous and vitreous, but they only
studied  2  proteins,  and  were  unable  to  demonstrate  how
generalized the phenomena is. By expanding the number of
proteins studied from 2 to 34, we were able to show that the
majority of the protein levels in the aqueous do not reflect
those  in  the  vitreous.  As  a  result  of  these  findings,  the
reliability of aqueous protein levels reflecting vitreous protein
levels must be tested for each protein biomarker of interest.
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